A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Netherton Syndrome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 12 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- BioCryst Pharmaceuticals
- Last updated on ClinicalTrials.gov
- August 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Stanford University School of Medicine · Palo Alto, CA
- Therapeutics Clinical Research · San Diego, CA
Connecticut · 1
- Yale Center for Clinical Investigation · New Haven, CT
Illinois · 1
- Northwestern Dermatology CTU · Chicago, IL
Indiana · 1
- Dawes Fretzin Clinical Research Group, LLC · Indianapolis, IN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.